A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OCAS / oral controlled absorption system

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OCAS  (>> Co-occurring Abbreviation)
Long Form:   oral controlled absorption system
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin. BPH, IPSS, LUTS, QOL
2016 Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. USSQ
2015 Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. AUR, FDC, IPSS, LUTS, SD, Soli, TUFS
2015 Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. BPH, LUTS
2014 Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies. AE
2013 A phase II dose-ranging study of mirabegron in patients with overactive bladder. ER
2013 Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. FDC, IPSS, LUTS, QOL, TOCAS, TUFS
2013 Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. AEs, GMR
2013 Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). IPSS, LUTS, QOL
10  2013 Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. CI
11  2012 Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. AE, OAB, PK
12  2011 The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study. BPH, HUS, IIEF, IPSS, LUTS, N-QOL
13  2010 Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. MR
14  2008 Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. ---
15  2007 A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. ER, KHQ, OAB, QOL
16  2007 [Impact of nocturia on the daily life of patients with lower urinary tract symptoms due to benign prostatic hyperplasia]. ---
17  2006 Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. ---
18  2006 Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). CV, DBP, OTs, PE, TPR